RECORDATI
Highly Engaged Employees
Highly Engaged EmployeesManufacturing · Italy · 1K - 5K Employees
View Company Info for Free
Overview
Headquarters
Via Matteo Civitali 1, Milano, Lombardy,...Phone Number
+39 2487871Website
www.recordati.comRevenue
$3.1 BillionStock Symbol
RECIndustry
ZI Rank: 1
Signal Type
Feb
Mar
Apr
May
Jun
Jul
ZI Rank
1
1
1
1
1
1
About RECORDATI
Recordati Industria Chimica e Farmaceutica S.p.A., together with its subsidiaries, engages in the research, development, manufacture, marketing, and sale of pharmaceuticals worldwide. The company offers pharmaceuticals in various therapeutic areas, including cardiovascular, dermatology, over the counter/non-prescription pharmaceuticals, urology, anti-infectives, central nervous system, gastrointestinal, gynecology and obstetrics, musculo-skeletal disorders and analgesia, nutrition and related products, cosmetics, dietary supplements, medical devices, allergy, endocrinology, respiratory, pain management/inflammation, generics, antipyretics and cold preparations, and oncology, as well as ear, nose, and throat. It also provides products for rare diseases; and pharmaceutical chemicals, such as chemical syntheses, active pharmaceutical ingredients, and intermediates. The company was founded in 1926 and is headquartered in Milan, Italy. Recordati Industria Chimica e Farmaceutica S.p.A. operaRead more
RECORDATI Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is RECORDATI your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Earning: See what the market has to say on RECORDATI recently announced quarterly report
Congratulate Masked Content for being promoted to Masked Content at RECORDATI
Website visits: Recent activity has been detected on your website
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Product Launch: Get notified when RECORDATI launches new products
Check out if RECORDATI is spiking on competitors!
Click to see if RECORDATI had a recent Job posting/layoffs
RECORDATI, which may be a good buyer, showed buying intent in Masked Content Topic
Check if RECORDATI has recently received funding, and reach out quickly before it becomes old news!
Funding: Get notified immidiatlly once RECORDATI has new funding data
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find more new buyers
Company Profile Activity
Activity Insights
RECORDATI is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
RECORDATI is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about RECORDATI.
RECORDATI Tech Stack
A closer look at the technologies used by RECORDATI
Most Recent Scoops
Earnings
RECORDATI has reported Rare Diseases segment revenues of EUR 604 million for H1, reflecting an increase of 17.1%, or 22% at constant exchange rates, with broad-based growth across the portfolio led by endocrinology and hemoncology.
Earnings
RECORDATI has reported urology revenue increased 1% in H1, driven by continued strong performance of ELIGARD supported by solid underlying demand and a temporary competitor stock-out in Turkey, largely offset by a more challenging comparison for TERGYNAN.
Earnings, Pharmaceuticals, Finance
Earnings
RECORDATI has reported gross profit increased 14.3% in H1, with gross margin improving to 71.5%, benefiting from strong operational performance, a positive mix effect, and the absence of prior year acquisition-related inventory charges.
Earnings, Finance
Earnings
RECORDATI has reported cardiovascular revenue declined 1.6% in H1, reflecting the anticipated impact of the loss of Cardicor and lower sales of certain mature products, partly offset by EUR 14 million in revenue from ESCAPE and ongoing growth from pitavastatin.
Earnings, Finance
Earnings
Earnings, Finance
RECORDATI News & Media
RECORDATI CELEBRATES ITS FIRST 100 YEARS AT TRIENNALE MILANO WITH AN EXHIBITION REVEALING OBJECTS AND IMAGES FROM ITS HISTORICAL ARCHIVE FOR THE FIRST TIME
IN TRIENNALE MILANO, RECORDATI CELEBRA I SUOI PRIMI 100 ANNI CON UNA MOSTRA CHE SVELA PER LA PRIMA VOLTA OGGETTI E IMMAGINI DEL SUO ARCHIVIO STORICORECORDATI: STRONG MOMENTUM OF THE GROUP CONTINUES INTO THE FIRST QUARTER OF 2026 NET REVENUE +4.9%, EBITDA(1) +5.0%, ADJUSTED NET INCOME(2) +7.2%
RECORDATI: STRONG MOMENTUM OF THE GROUP CONTINUES INTO THE FIRST QUARTER OF 2026 NET REVENUE +4.9%, EBITDA +5.0%, ADJUSTED NET INCOME +7.2%RECORDATI REPORTS STRONG PRELIMINARY FULL YEAR 2025 RESULTS: REVENUE +11.8%, EBITDA(1) +14.5%, ADJUSTED NET INCOME(2) +14.5%
RECORDATI REPORTS STRONG PRELIMINARY FULL YEAR 2025 RESULTS: REVENUE +11.8%, EBITDA +14.5%, ADJUSTED NET INCOME +14.5%RECORDATI ANNOUNCES STRATEGIC COLLABORATION WITH MODERNA TO DEVELOP AND COMMERCIALIZE WORLDWIDE mRNA 3927 FOR THE TREATMENT OF PROPIONIC ACIDEMIA
RECORDATI ANNOUNCES STRATEGIC COLLABORATION WITH MODERNA TO DEVELOP AND COMMERCIALIZE WORLDWIDE mRNA 3927 FOR THE TREATMENT OF PROPIONIC ACIDEMIA
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding RECORDATI
Sign Up For FreeTo access detailed company insights
Recordati Industria Chimica e Farmaceutica S.p.A., together with its subsidiaries, engages in the research, development, manufacture, marketing, and sale of pharmaceuticals worldwide. The company offers pharmaceuticals in various therapeutic areas, including cardiovascular, dermatology, over the counter/non-prescription pharmaceuticals, urology, an... Read More
